Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

  • Roman Hájek1Email author,
  • Richard Bryce2, 4,
  • Sunhee Ro2,
  • Barbara Klencke2 and
  • Heinz Ludwig3
BMC Cancer201212:415

DOI: 10.1186/1471-2407-12-415

Received: 16 February 2012

Accepted: 31 July 2012

Published: 19 September 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
16 Feb 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
8 Jun 2012 Reviewed Reviewer Report - Nikoletta Lendvai
16 Jun 2012 Reviewed Reviewer Report - Craig Hofmeister
6 Jul 2012 Author responded Author comments - Roman Hajek
Resubmission - Version 4
6 Jul 2012 Submitted Manuscript version 4
24 Jul 2012 Author responded Author comments - Roman Hajek
Resubmission - Version 5
24 Jul 2012 Submitted Manuscript version 5
Publishing
31 Jul 2012 Editorially accepted
19 Sep 2012 Article published 10.1186/1471-2407-12-415

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Internal Medicine -Haematooncology, University Hospital Brno and Faculty of Medicine Ostrava
(2)
Onyx Pharmaceuticals, Inc
(3)
Wilhelminen Hospital
(4)
Present affiliation: Puma Biotechnology, Inc

Advertisement